Business
Retail Cannabis Investors Paved the Way for Institutional Investors to Jump in - How CIBC, Piper Jaffray and Peter Thiel are Playing a Role in Cannabis Stocks
Retail Cannabis Investors Paved the Way for Institutional Investors to Jump in - How CIBC, Piper Jaffray and Peter Thiel are Playing a Role in Cannabis Stocks.
About this update from American Premium Water Corporation
[{"type":"text","content":"\nPOINT ROBERTS, Wash. and DELTA, British Columbia, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Investorideas.com, a leading investor news resource covering hemp and cannabis stocks releases a snapshot looking at the growing trend of institutional coverage and funding in the cannabis sector and how a once frowned upon industry is now the big-boys new ‘darling’.\n In any industry that builds success, history shows the little companies lead innovation and take the risk and once the value proposition is proven, the big companies step in to grab their share. The same can hold true for investing; small retail investors see the big picture before the institutional investors - and never has this pattern been more true than with the cannabis sector. Retail investors can pat themselves on the back following Friday’s news that CIBC's Institutional Equity Research team initiated coverage on Canopy Growth, Cronos and Aphria. In their report, ‘Cannabis: The Beginning of a Global Seismic Shift’, they stated: Our Conclusion: “Investors rarely get to witness the birth of an industry. Such historic events include the gold rush, inventions of the automobile and aircraft, and the internet. In most instances, investors rush to pour capital into the sector, and while the industries develop, very few companies live up to their lofty expectations. We expect cannabis to follow this course. Dozens of small/medium-sized firms will likely earn moderate revenues and earnings, but our view is that only a handful will come to dominate the global market. We believe Canopy and Cronos are likely to be two of those winners; meanwhile, we view Aphria as a manufacturing and automation expert, but believe concerns about capital allocation and corporate governance could deter investors. Effective January 17, we initiate coverage of Canopy Growth with an Outperformer rating and $65 price target; Cronos Group, with an Outperformer rating and $22 price target; and Aphria, with a Neutral rating and $10 price target.” Retail investors usually see a bump in the share price once the bigger institutional investors step in and that was  definitely the case following the January 15th news from CBD beverage company, American Premium Water Corporation (OTC: HIPH) that it had entered into a financing agreement with an institutional inves...